Loading
Takeda Pharmaceutical Co Ltd Stock: price and insider trades · United States
US·Mcap US$62.8B
Takeda Pharmaceutical Co Ltd: what insiders have been doing
Takeda Pharmaceutical Co Ltd is a listed company. Filings by its managers are published through SEC (Form 4). Between 18 October 2025 and 18 October 2026, 39 insiders published 73 filings.
All open-market trades in the period are sales: 20 sales worth €11.3M, by 13 insiders, with no purchase on record. Biggest ticket of the year: €2.4M, sold by Plump Andrew Stewart and made public on 12 August 2026 (0.0047% of market cap).
With 73 filings in twelve months, the company is more active than the median of 22 filings across the 5,458 companies we follow on the same exchange. Over the whole record (from 2026), the tally stands at no purchases and 20 sales.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.
For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
73
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€11M
20 ops. · all time
Who traded when
BuySaleNicola Deidre Petal Greenway4 sales
Andrew Stewart Plump3 sales
Elaine Mary Shannon2 sales
Lauren Rusckowski Duprey2 sales
Agosti Marcello Pignagnoli1 sale
Awny Samaan Botros Farajallah1 sale
+7 other insiders
Analyst consensus: bullish or bearish?
Analysts rate Takeda Pharmaceutical Co Ltd Strong Buy (bullish), based on 3 analysts. Average price target: US$22.75.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 9,626 of 24,148 companies
56.7
score / 100
Value79
Quality35
FCF yld·
Earn yld·
EV/EBITDA6.8x
ROE-2.3%
Gross mgn65%
Net mgn-3.4%
Debt/EBITDA6.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
US$19.67
Analyst consensus
3 analystsStrong buy
US$21.05Target US$22.75(+16%)US$25.14
Income statement
RevenueUS$4.5T
Gross profitUS$2.9T65% margin
EBITDAUS$726.9B16% margin
Net income-US$152.4B-3.5% margin
Valuation
P/Book1.3x
Beta0.10
Balance sheet & cash
Market capUS$62.8B
Total debtUS$4.9T
Free Cash FlowUS$626.8B
Debt / Equity73%
Profitability & ownership
ROE-2.3%
ROA2.7%
% insiders0.1%
% institutions3.3%
Last declaration on 15 September 2026
Declarations73 total
34,535 shares@ US$18.540.0011% mcap44.0% of flowAmerican Depositary SharesSEC:0001395064-26-000340:0
34,535 shares@ US$18.370.0011% mcap41.8% of flowAmerican Depositary Shares (ADSs)SEC144:0001493152-26-042079
116,191 shares@ US$18.490.0036% mcap37.6% of flowAmerican Depositary SharesSEC:0001395064-26-000335:0
19,651 shares@ US$18.490.0006% mcap6.4% of flowAmerican Depositary SharesSEC:0001493152-26-039693:0
19,651 shares@ US$18.49010.0006% mcap6.4% of flowCommonSEC144:0001959173-26-006231
12,980 shares@ US$18.11390.0004% mcap24.5% of flowAmerican Depositary SharesSEC:0001493152-26-039214:0
12,980 shares@ US$17.390.0004% mcap64.4% of flowAmerican Depositary Shares (ADSs)SEC144:0001493152-26-038353
50,012 shares@ US$17.100.0014% mcap100.0% of flowAmerican Depositary SharesSEC:0001493152-26-037502:0
47,586 shares@ US$17.100.0014% mcap56.0% of flowAmerican Depositary SharesSEC:0001493152-26-037509:0
14,006 shares@ US$17.100.0004% mcap100.0% of flowAmerican Depositary SharesSEC:0001493152-26-037515:0
30,868 shares@ US$17.100.0009% mcap100.0% of flowAmerican Depositary SharesSEC:0001493152-26-037480:0
975 shares@ US$17.500.0000% mcap1.8% of flowAmerican Depositary SharesSEC:0001493152-26-037351:0
33,628 shares@ US$17.50670.0010% mcap61.6% of flowAmerican Depositary SharesSEC:0001493152-26-037351:1
6,774 shares@ US$17.100.0002% mcap12.1% of flowAmerican Depositary SharesSEC:0001493152-26-037486:0
7,277 shares@ US$17.100.0002% mcap100.0% of flowAmerican Depositary SharesSEC:0001493152-26-037514:0
89,090 shares@ US$17.100.0025% mcap100.0% of flowAmerican Depositary SharesSEC:0001493152-26-037484:0
16,901 shares@ US$17.100.0005% mcap100.0% of flowAmerican Depositary SharesSEC:0001493152-26-037513:0
22,957 shares@ US$17.100.0007% mcap100.0% of flowAmerican Depositary SharesSEC:0001493152-26-037505:0
31,083 shares@ US$17.100.0009% mcap100.0% of flowAmerican Depositary SharesSEC:0001493152-26-037482:0
165,393 shares@ US$17.100.0047% mcap49.6% of flowAmerican Depositary SharesSEC:0001493152-26-037507:0
25,088 shares@ US$17.100.0007% mcap100.0% of flowAmerican Depositary SharesSEC:0001493152-26-037494:0
20,363 shares@ US$17.550.0006% mcap84.0% of flowAmerican Depositary SharesSEC:0001493152-26-037352:0
3,978 shares@ US$17.100.0001% mcap16.0% of flowAmerican Depositary SharesSEC:0001493152-26-037499:0
20,363 shares@ US$17.45American Depositary Shares (ADSs)SEC144:0001493152-26-036878
34,603 shares@ US$16.720.0010% mcap82.3% of flowAmerican Depositary Shares (ADSs)SEC144:0001493152-26-036402
25 of 73 declarations
About Takeda Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd is a Japanese pharmaceutical company focused on the research and development of innovative medicines. It specializes in therapeutic areas such as oncology, rare diseases, and gastrointestinal disorders.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
